A dilemma no mother-to-be should face
31 January 2018
Clair faced an impossible choice – risk delivering her baby early, or delay potentially life-saving melanoma treatment.
She was 38 weeks’ pregnant with her first child when she received the news that a suspicious looking mole on her face was melanoma. Her medical team advised her she needed urgent surgery to remove the melanoma.
“It was pretty scary,” Clair said. “We discussed getting me into surgery that week but that would require knocking me out and with that there was a great risk of me going into labour in the operating theatre and waking up with my baby. That wasn’t something I wanted.”
Luckily, Clair and her medical team were able to formulate a plan which enabled her to give birth to her son and then have the surgery shortly afterwards.
“You’re breast feeding at the time, you have to fast for the surgery, you’re away from your baby - you have all those fears running through your mind,” Clair recalls.
Clair’s surgery was a success and she has since had three more children. She is grateful her employer, Brightside Cover, is supporting melanoma research by coming on board as Principal Partner for Melanoma March.
Clair’s is the latest in a series of emotive videos launched by Melanoma Institute Australia, showing the impact of melanoma on everyday Australians. Watch her story here and join her in the fight against melanoma by signing up for a Melanoma March event near you.
Join us at the 2nd Melanoma Patients Australia webinar 'Psychological Health & Wellbeing'.
You're invited to be a C2S charity superstar, and together we can run over melanoma!
Join in the fun of the virtual event, and together we can run over melanoma!
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.
We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.
A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.